EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Epidemiological shifts of invasive fungal infections in the current era of haematology

Patricia Monzo-Gallo, Christian Teijon-Lumbreras, Tommaso Francesco Aiello, Antonio Gallardo-Pizarro iD, Ana Martinez-Urrea, Mariana Chumbita, Emmanuelle Gras, Olivier Peyrony, Marta Bodro, Laura Magnano, Sabina Herrera, Maria Suarez-Lledó und 4 weitere

Medical Mycology · 2025

DOI: 10.1093/mmy/myaf070 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medical Mycology, 2025. Verfasst von Patricia Monzo-Gallo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain. Hauptthemen laut MEDLINE: Invasive Fungal Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: SGR, AGAUR, Institut de Salut Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aim to describe the epidemiology and risk factors for invasive fungal infections (IFI) and invasive mould infections (IMI) in hospitalized hematologic patients within the context of current hematologic therapies. Retrospective observational cohort study conducted on consecutive hematologic patients admitted to a tertiary hospital (2020–2023). Two populations were analysed: the full cohort of hospitalized patients (FC) and the subset of patients for whom mycological testing was specifically requested to rule out an IFI (SC). Proven or probable IFI was classified using European Organization for Research and Treatment of Cancer criteria. Risk factors for IFI and IMI were identified. A total of 1975 patients were included in the FC, whereas 1154 were included in the SC. IFI was diagnosed in 64 patients (65 episodes), and IMI in 43 patients (44 episodes). Aspergillosis was the most common IFI (58.4%), followed by candidemia (18.5%), Pneumocystis jirovecii pneumonia (PJP) (15.4%), mucormycosis (6.2%), and fusariosis (4.6%). Independent risk factors for IFI in the FC included acute leukemia (aOR 2.40, 95% CI 1.37–4.10, P = .002), corticosteroid use (aOR 2.36, 95% CI 1.40–4.03, P = .001) and graft versus host disease (GVHD) (aOR 2.13, 95% CI 0.93–4.46, P = .05). For IMI, risk factors were acute leukemia (aOR 2.71, 95% CI 1.33–5.52, P = .006), corticosteroid use (aOR 1.96, 95% CI 0.98–4.03, P = .05) and chronic lung disease (aOR 2.25, 95% CI 1.06–4.5, P = .02). In the SC, corticosteroid use (aOR 2.45, 95% CI 1.44–4.25, P = .001) was the independent risk factor for IFI, and corticosteroid use (aOR 2.40, 95% CI 1.21–4.91, P = .01) and GVHD (aOR 2.95, 95% CI 1.23–6.52, P = .009) were independent factors associated with IMI. Mortality was significantly higher in IFI patients compared to non-IFI patients (51.6% vs. 20.3%, P < .001). In this new era of haematology, the epidemiology of IFI is shifting, with Pneumocystis, Mucorales, and Fusarium becoming more prevalent. While corticosteroids and GVHD remain key risk factors, factors such as chronic lung disease are increasing its importance. Prolonged neutropenia may have decreased in relevance, likely due to prophylaxis. Preventing PJP has become a new challenge in IFI management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Fungal InfectionsHumansMaleFemaleMiddle AgedRetrospective StudiesRisk FactorsAgedAdultTertiary Care CentersAged, 80 and overHematologic NeoplasmsYoung Adult

Stichwörter der Autor:innen

aspergillosishematologic malignanciesinvasive fungal infection

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain.
  • Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), c. Casanova, 143, 08036 Barcelona, Spain.
  • Institut Pierre Louis d'Épidémiologie et de Santé Publique, INSERM, Sorbonne University, 75013 Paris, France.
  • Emergency Department, Hôpital Saint Louis, Assistance Publique-Hôpitaux, 75010 Paris, France.
  • Department of Haematology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
  • Department of Microbiology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.

ORCID-Profile: Antonio Gallardo-Pizarro, Francesc Marco, Alex Soriano, Carolina Garcia-Vidal

Förderung

  • SGR
  • AGAUR
  • Institut de Salut Carlos III
  • European Union-Next GenerationEU
  • Ministerio de Sanidad y Consumo
  • Instituto de Salud Carlos III
  • European Union—Next GenerationEU

Zitieren

APA

Monzo-Gallo, P., Teijon-Lumbreras, C., Aiello, T. F., Gallardo-Pizarro, A., Martinez-Urrea, A., Chumbita, M., Gras, E., Peyrony, O., Bodro, M., Magnano, L., Herrera, S., Suarez-Lledó, M., Espasa, M., Marco, F., Soriano, A., & Garcia-Vidal, C. (2025). Epidemiological shifts of invasive fungal infections in the current era of haematology. Medical Mycology. https://doi.org/10.1093/mmy/myaf070

Vancouver

Monzo-Gallo P, Teijon-Lumbreras C, Aiello TF, Gallardo-Pizarro A, Martinez-Urrea A, Chumbita M, et al. Epidemiological shifts of invasive fungal infections in the current era of haematology. Medical Mycology. 2025. doi:10.1093/mmy/myaf070

BibTeX
@article{MonzoGallo2025,
  author = {Monzo-Gallo, Patricia and Teijon-Lumbreras, Christian and Aiello, Tommaso Francesco and Gallardo-Pizarro, Antonio and Martinez-Urrea, Ana and Chumbita, Mariana and Gras, Emmanuelle and Peyrony, Olivier and Bodro, Marta and Magnano, Laura and Herrera, Sabina and Suarez-Lledó, Maria and Espasa, Mateu and Marco, Francesc and Soriano, Alex and Garcia-Vidal, Carolina},
  title = {Epidemiological shifts of invasive fungal infections in the current era of haematology},
  journal = {Medical Mycology},
  year = {2025},
  doi = {10.1093/mmy/myaf070}
}
Kostenlos starten →